<?xml version="1.0" encoding="UTF-8"?> <!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd"> <ArticleSet> <Article> <Journal> <PublisherName>jmedicalcasereports</PublisherName> <JournalTitle>Frontiers in Medical Case Reports</JournalTitle> <PISSN>I</PISSN> <EISSN>S</EISSN> <Volume-Issue>Volume 2; Issue 2, (Jul-Dec,2021)</Volume-Issue> <PartNumber/> <IssueTopic>Multidisciplinary</IssueTopic> <IssueLanguage>English</IssueLanguage> <Season>Cancer Case Reports</Season> <SpecialIssue>N</SpecialIssue> <SupplementaryIssue>N</SupplementaryIssue> <IssueOA>Y</IssueOA> <PubDate> <Year>-0001</Year> <Month>11</Month> <Day>30</Day> </PubDate> <ArticleType>Cancer Case Reports</ArticleType> <ArticleTitle>A Novel Effective Treatment of Advanced Prostate Cancer: A Single Case Report</ArticleTitle> <SubTitle/> <ArticleLanguage>English</ArticleLanguage> <ArticleOA>Y</ArticleOA> <FirstPage>1</FirstPage> <LastPage>6</LastPage> <AuthorList> <Author> <FirstName>Rolf</FirstName> <LastName>Seljelid</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>N</CorrespondingAuthor> <ORCID/> <FirstName>Jarl</FirstName> <LastName>Bøgwald</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> </Author> </AuthorList> <DOI/> <Abstract>A novel treatment for prostate cancer, based on the Tvec /pembroluzimab technology – supported by activation of innate immunity is reported. The effect has been striking. Reduction of PSA from 60 µg/Liter to undetectable in 6 weeks, reduction of serum LDH from almost 1000 U/L to under 200 (normal) in 8 weeks, extensive necrosis in the tumor tissue as revealed by MR. The treatment gave no serious side-effects.</Abstract> <AbstractLanguage>English</AbstractLanguage> <Keywords>Prostate,Cancer,Tvec,Pembroluzimab,Innate Immunity</Keywords> <URLs> <Abstract>https://www.jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=15148&title=A Novel Effective Treatment of Advanced Prostate Cancer: A Single Case Report</Abstract> </URLs> <References> <ReferencesarticleTitle>References</ReferencesarticleTitle> <ReferencesfirstPage>16</ReferencesfirstPage> <ReferenceslastPage>19</ReferenceslastPage> <References>Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 9th edition, Elsevier, 2017 Bogwald J, Hoffman J, Seljelid R. Coupling of polysaccharides by means of chloroacetaldehyde dimethyl acetal to amines or protein by reductive amination. Carbohydrate Res 1986; 148: 101-107. Gordon S. The macrophage: Past, present and future. Eur J Immunol 2007; 37: S9-S17. Kohlhapp FJ and Kaufman HL. Molecular Pathways: Mechanism of Action for Talimogens Laherparepvcc, a New Oncolytic Virus Immunotherapy. Clinical Cancer Res 2016; 22: 1048. Li Y, Cozzi PJ, Russell P. Promising tumor-associated antigens for future prostate cancer therapy. Medicinal Research Reviews 2010; 30: 67-101. Paul WE. Fundamental Immunology. Wolters Kluwer Health/Lippincott Williams and; Wilkins, Philadelphia, 2013. Seljelid R, Bogwald J, Lundwall A. Glycan stimulation of macrophages in vitro. Exp Cell Res 1981; 13: 121-129. Seljelid R, Rasmussen LT, Larm O, Hoffman J. The protective effect of beta 1-3 D-glucan derivatized plastic beads against Escherichia coli infection in mice. Scand J Immunol 1987; 25: 55-60. Seljelid R. A watersoluble aminated and;szlig;1-3 glucan Derivative causes Regression of Solid Tumors in mice. Bioscience Reports 1986; 9: 845-851. Seljelid R. Tumour Regression after Treatment with aminated and;szlig;1-3 polyglucose is initiated by circulatory failure. Scand J Immunol 1989; 29: 181-192. Sweeney K and Halldand;eacute;n G. Oncolytic adenovirus – mediated therapy for Prostate cancer. Oncolytic Virotherapy 2012; 5: 45-57. Trehub Y and Gavrilov A. Oncolytic virus in Immunotherapeutic Agents. In Springer Nature Cancer Immunology Rezaei N. (Ed.) 2021; 2021: 509-541.</References> </References> </Journal> </Article> </ArticleSet>